Pet project

24 October 2017 By Robert Cyran

The $90 bln outfit is weighing the sale or float of its pet and livestock drug business. Lofty valuations make it tempting to raise cash when the firm’s core pharma business has pipeline stumbles. But FDA approval for its arthritis treatment is the real prescription investors seek.

This content is for Subscribers only

To access full Breakingviews.com content you must be a subscriber. Please use the following link to request a trial.

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)